Microbot Medical Inc.(MBOT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.4M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MBOT Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Microbot Medical Inc. (MBOT), a Healthcare sector company. MBOT is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.4m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Microbot Medical Inc. reports quarterly revenue of $241.0K, net income of $-5.6M, free cash flow of $-5.1M. Top institutional holders of MBOT by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Mitsubishi UFJ Asset Management , Ltd., BlackRock, based on the most recent SEC filings. MBOT trades on the Nasdaq exchange and files with the SEC under CIK 883975. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MBOT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Microbot Medical Inc. directly from SEC EDGAR.
Revenue
Q2 2026
$241.0K
Net Income
Q2 2026
$-5.6M
Free Cash Flow
Q2 2026
$-5.1M
ROIC
Q2 2026
-35.9%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-14.8% YoYOperating Income
-26.8% YoYEPS (Diluted)
+60.3% YoYTotal Assets
+1252.1% YoYOp. Cash Flow
-47.8% YoYFree Cash Flow
-48.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-13.1M -14.8% | $-11.4M -6.5% | $-10.7M +18.4% | $-13.2M -16.4% | $-11.3M -23.4% | $-9.2M |
| Operating Income | $-14.7M -26.8% | $-11.6M -18.0% | $-9.9M +25.8% | $-13.3M -16.9% | $-11.4M -25.0% | $-9.1M |
| EPS (Diluted) | $-0.29 +60.3% | $-0.73 +30.5% | $-1.05 +42.0% | $-1.81 | — | — |
| Total Assets | $81.5M +1252.1% | $6.0M -27.6% | $8.3M -12.7% | $9.5M -43.1% | $16.8M -36.2% | $26.3M |
| Operating Cash Flow | $-13.0M -47.8% | $-8.8M -3.4% | $-8.5M +26.1% | $-11.5M -23.5% | $-9.4M -29.0% | $-7.3M |
| Free Cash Flow | $-13.1M -48.1% | $-8.9M -3.3% | $-8.6M +26.4% | $-11.6M -23.5% | $-9.4M -28.3% | $-7.3M |
Get alerted when MBOT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Microbot Medical Inc. including:
Top Institutional Holders of MBOT
VANGUARD CAPITAL MANAGEMENT LLC
$5.7M2,906,810 shMitsubishi UFJ Asset Management Co., Ltd.
$2.5M1,268,453 shBlackRock, Inc.
$1.8M902,411 shGEODE CAPITAL MANAGEMENT, LLC
$1.6M836,271 shUBS Group AG
$1.6M806,847 shDnB Asset Management AS
$1.3M677,498 shSTIFEL FINANCIAL CORP
$1.2M589,924 shMARSHALL WACE, LLP
$1.1M541,963 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$1.0M525,827 shVANGUARD FIDUCIARY TRUST CO
$840.5K431,033 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $5.7M | 2,906,810 |
| Mitsubishi UFJ Asset Management Co., Ltd. | $2.5M | 1,268,453 |
| BlackRock, Inc. | $1.8M | 902,411 |
| GEODE CAPITAL MANAGEMENT, LLC | $1.6M | 836,271 |
| UBS Group AG | $1.6M | 806,847 |
| DnB Asset Management AS | $1.3M | 677,498 |
| STIFEL FINANCIAL CORP | $1.2M | 589,924 |
| MARSHALL WACE, LLP | $1.1M | 541,963 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.0M | 525,827 |
| VANGUARD FIDUCIARY TRUST CO | $840.5K | 431,033 |
More Healthcare Companies
View all Healthcare →Put MBOT on your watchlist
Track score changes the day Microbot Medical Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MBOT a good stock to buy?
13F Pro's AI-powered analysis of Microbot Medical Inc. (MBOT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MBOT are available on the MBOT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MBOT is classified as a small company.
Which hedge funds own MBOT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MBOT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Microbot Medical Inc.'s investment landscape.